近日,亚盛医药在其核心产品耐立克®(奥雷巴替尼)的研发上再次传来捷报——该药在胃肠道间质瘤领域的研究进展发表于国际权威期刊《Signal Transduction and Targeted Therapy》。与此同时,亚盛医药在资本市场的表现同样引人注目。自2025年1月24日成功登陆纳斯达克,成为当年美股生物医药第一股以来,亚盛医药港股股价年内翻倍,刷新上市新高。在生物医药产业资本寒气未散的大...
Source Link近日,亚盛医药在其核心产品耐立克®(奥雷巴替尼)的研发上再次传来捷报——该药在胃肠道间质瘤领域的研究进展发表于国际权威期刊《Signal Transduction and Targeted Therapy》。与此同时,亚盛医药在资本市场的表现同样引人注目。自2025年1月24日成功登陆纳斯达克,成为当年美股生物医药第一股以来,亚盛医药港股股价年内翻倍,刷新上市新高。在生物医药产业资本寒气未散的大...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.